Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
On 2026-07-21, Acrivon Therapeutics Chief Legal Officer Mary Miller had 573 shares of Common Stock sold at $1.76 per share. A note explains that the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units. She continues to hold 82,194 shares directly after the transaction.
Acrivon Therapeutics, Inc. reported that entities affiliated with RA Capital are associated with a new stock option grant linked to director Dr. Derek DiRocco. The derivative award covers 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests on the day before Acrivon’s next annual stockholder meeting, conditioned on Dr. DiRocco’s continued service. According to the disclosures, Dr. DiRocco holds the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, and any net value from exercise will offset advisory fees owed to RA Capital Management, L.P., while the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics director Michael John Tomsicek received a stock option grant covering 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares are reported as held directly after this grant. The filing states that these options will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided he remains in continuous service through that vesting date. This is a compensation-related award and does not reflect an open-market purchase or sale of shares.
Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036.
All 20,275 option shares remain held following the transaction. According to the grant terms, these options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided Shacham continues to serve through that vesting date.
Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares remain held following the grant. The option will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, conditioned on Santhosh’s continuous service through that vesting date.
Acrivon Therapeutics director Ivana Magovcevic-Liebisch received a new stock option grant. She was granted options to acquire 20,275 shares of Acrivon Therapeutics common stock at an exercise price of $1.52 per share.
The options are a compensation-related award, not an open-market purchase. They vest on the date immediately preceding the company’s next annual meeting of stockholders, as long as she remains in continuous service through that vesting date. Following this grant, she holds stock options for 20,275 underlying shares directly.
Acrivon Therapeutics director Derek DiRocco was granted a stock option covering 20,275 shares of common stock at an exercise price of $1.52 per share, expiring on June 16, 2036. The option vests immediately before Acrivon’s next annual stockholder meeting, subject to his continuous service.
The option is held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Any net cash or stock from exercise must be turned over to RA Capital Management, L.P., and DiRocco disclaims beneficial ownership of the option and underlying shares.
Acrivon Therapeutics director Charles M. Baum received a grant of stock options for 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036. All 20,275 options will vest immediately before Acrivon’s next annual stockholder meeting, contingent on his continuous service.
Acrivon Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders approved an Amended and Restated 2022 Equity Incentive Plan. The plan authorizes up to 8,606,723 shares of common stock for equity awards, including an increase of 3,000,000 shares approved at the meeting, and features an annual automatic share reserve increase of 5% of fully diluted shares through 2032 unless the Board sets a lower amount.
Shareholders also elected Michael Tomsicek and Charles Baum as Class I directors to serve until the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approved the amended equity plan. A quorum of 31,336,993.43 shares, representing 73.21% of shares entitled to vote as of April 23, 2026, was present or represented by proxy.
Acrivon Therapeutics reported a routine insider equity adjustment involving its President and CEO, Dr. Peter Blume-Jensen, and EVP of Business Operations, Dr. Kristina Masson. The company withheld 13,729 shares of common stock at $1.79 per share to cover mandatory taxes upon the vesting of restricted stock units, a non‑market transaction classified as a tax-withholding disposition. Following this, Dr. Blume-Jensen directly holds 2,245,317 shares of common stock, and the filing also lists 386,343 shares of common stock as indirectly held between the spouses, with each disclaiming beneficial ownership beyond their pecuniary interest.